This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Uppthera. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovative Mind of Hyeong Seok Lee
Introduction
Hyeong Seok Lee, an inventive mind based in Incheon, South Korea, is making significant strides in biotechnology through his innovative work. With a focus on novel medical treatments, Lee has secured a patent that showcases his expertise in the field, solidifying his status as a noteworthy inventor in the scientific community.
Latest Patents
Lee's most recent patent, titled "Cell-penetrating cereblon recombinant fusion protein and use thereof," involves a groundbreaking recombinant fusion protein. This innovation includes a peptide domain consisting of the amino acid sequence of SEQ ID NO: 1 and another peptide domain with the amino acid sequence of SEQ ID NO: 2. The novel cell-penetrating cereblon recombinant fusion protein holds promise for the prevention or treatment of cereblon-related diseases, indicating Lee's commitment to advancing medical biotechnology.
Career Highlights
Currently, Hyeong Seok Lee is employed at Uppthera, a company at the forefront of therapeutic development. His role involves significant contributions to research and innovation in biotechnology. Lee's expertise and focus on cell-penetrating proteins showcase his dedication to improving health outcomes through scientific advancement.
Collaborations
Throughout his career, Lee has collaborated with notable peers, including SooHee Ryu and Hwa Jin Lee. These partnerships exemplify the collaborative spirit within the scientific community and highlight the importance of teamwork in advancing research and innovation in biotechnology.
Conclusion
Hyeong Seok Lee is an inspiring figure in the field of biotechnology, with a clear vision for translating innovative ideas into practical applications. His patent on the cell-penetrating cereblon recombinant fusion protein signifies his commitment to enhancing medical treatments for cereblon-related diseases. As Lee continues to work at Uppthera, he undoubtedly remains a pivotal player in the advancement of therapeutic technologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile